98
Views
0
CrossRef citations to date
0
Altmetric
Review

Pain in Spinal Cord Injury

&
Pages 87-94 | Published online: 21 Dec 2011
 

Abstract

SUMMARY An important and detrimental effect of spinal cord injury (SCI) is pain, which develops in approximately two-thirds of all SCI patients, while approximately half of SCI patients develop chronic neuropathic pain (NP). Thus far, there is no cure for SCI NP, and oral pharmacological intervention is often inadequate, commonly resulting in a pain reduction of only 20–30%. In this short review, we will present an overview of the important features of SCI pain including taxonomy, epidemiology and classification, as well as a suggested oral pharmacological treatment strategy for SCI NP and the current evidence available from randomized placebo-controlled trials. Considerations and evidence for the nonpharmacological treatment of SCI will be discussed briefly.

Acknowledgements

The authors would like to thank research secretary HO Andersen for language revision.

Financial & competing interests disclosure

C Baastrup and NB Finnerup are supported by grants from the Velux Fonden. The authors are part of the Europain Project, funded by the Innovative Medicines Initiative Joint Undertaking, grant no. 115007. NB Finnerup has in the past year received honoraria from Grünenthal and C Baastrup has received a travel grant from Astellas Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

C Baastrup and NB Finnerup are supported by grants from the Velux Fonden. The authors are part of the Europain Project, funded by the Innovative Medicines Initiative Joint Undertaking, grant no. 115007. NB Finnerup has in the past year received honoraria from Grünenthal and C Baastrup has received a travel grant from Astellas Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 412.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.